Literature DB >> 33184998

Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes.

Kai Mi1, Fuhui Chen2, Zhipeng Qian1, Jing Chen1, Dongxu Lv1, Chunlong Zhang1, Yanjun Xu1, Hongguang Wang3,4, Yuepeng Zhang2, Yanan Jiang1,5,6, Desi Shang1.   

Abstract

Growing evidence has highlighted the immune response as an important feature of carcinogenesis and therapeutic efficacy in non-small cell lung cancer (NSCLC). This study focused on the characterization of immune infiltration profiling in patients with NSCLC and its correlation with survival outcome. All TCGA samples were divided into three heterogeneous clusters based on immune cell profiles: cluster 1 ('low infiltration' cluster), cluster 2 ('heterogeneous infiltration' cluster) and cluster 3 ('high infiltration' cluster). The immune cells were responsible for a significantly favourable prognosis for the 'high infiltration' community. Cluster 1 had the lowest cytotoxic activity, tumour-infiltrating lymphocytes and interferon-gamma (IFN-γ), as well as immune checkpoint molecules expressions. In addition, MHC-I and immune co-stimulator were also found to have lower cluster 1 expressions, indicating a possible immune escape mechanism. A total of 43 differentially expressed genes (DEGs) that overlapped among the groups were determined based on three clusters. Finally, based on a univariate Cox regression model, prognostic immune-related genes were identified and combined to construct a risk score model able to predict overall survival (OS) rates in the validation datasets.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  non-small cell lung cancer; prognostic; tumour microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33184998      PMCID: PMC7754023          DOI: 10.1111/jcmm.16092

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.295


  53 in total

1.  The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.

Authors:  Ming-Ching Lee; Daniel H Buitrago; Kyuichi Kadota; Hideki Ujiie; Kaitlin Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

2.  Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.

Authors:  David Taggart; Tereza Andreou; Karen J Scott; Jennifer Williams; Nora Rippaus; Rebecca J Brownlie; Elizabeth J Ilett; Robert J Salmond; Alan Melcher; Mihaela Lorger
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-31       Impact factor: 11.205

3.  Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.

Authors:  Giulia Mazzaschi; Denise Madeddu; Angela Falco; Giovanni Bocchialini; Matteo Goldoni; Francesco Sogni; Giovanna Armani; Costanza Annamaria Lagrasta; Bruno Lorusso; Chiara Mangiaracina; Rocchina Vilella; Caterina Frati; Roberta Alfieri; Luca Ampollini; Michele Veneziani; Enrico Maria Silini; Andrea Ardizzoni; Konrad Urbanek; Franco Aversa; Federico Quaini; Marcello Tiseo
Journal:  Clin Cancer Res       Date:  2017-10-26       Impact factor: 12.531

4.  CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.

Authors:  Kang-Seo Park; Mark Raffeld; Yong Wha Moon; Liqiang Xi; Caterina Bianco; Trung Pham; Liam C Lee; Tetsuya Mitsudomi; Yasushi Yatabe; Isamu Okamoto; Deepa Subramaniam; Tony Mok; Rafael Rosell; Ji Luo; David S Salomon; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

Review 5.  Cancer immune escape: MHC expression in primary tumours versus metastases.

Authors:  Federico Garrido; Natalia Aptsiauri
Journal:  Immunology       Date:  2019-10-01       Impact factor: 7.397

6.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors:  D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 7.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).

Authors:  Patrick Danaher; Sarah Warren; Rongze Lu; Josue Samayoa; Amy Sullivan; Irena Pekker; Brett Wallden; Francesco M Marincola; Alessandra Cesano
Journal:  J Immunother Cancer       Date:  2018-06-22       Impact factor: 13.751

10.  Anatomical Involvement of the Subventricular Zone Predicts Poor Survival Outcome in Low-Grade Astrocytomas.

Authors:  Shuai Liu; Yinyan Wang; Xing Fan; Jun Ma; Wenbin Ma; Renzhi Wang; Tao Jiang
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

View more
  7 in total

1.  Apolipoprotein D as a Potential Biomarker and Construction of a Transcriptional Regulatory-Immune Network Associated with Osteoarthritis by Weighted Gene Coexpression Network Analysis.

Authors:  Yong Qin; Jia Li; Yonggang Zhou; Chengliang Yin; Yi Li; Ming Chen; Yinqiao Du; Tiejian Li; Jinglong Yan
Journal:  Cartilage       Date:  2021-10-31       Impact factor: 3.117

2.  Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures.

Authors:  Guohong Gao; Zhilong Yu; Xiaoyan Zhao; Xinyi Fu; Shengsheng Liu; Shan Liang; Aijun Deng
Journal:  Sci Rep       Date:  2021-11-15       Impact factor: 4.379

3.  Identification and Validation of an Immune and Ferroptosis-Combined Index for Non-Small Cell Lung Cancer.

Authors:  Yang Teng; Bo Wang; Desi Shang; Ning Yang
Journal:  Front Genet       Date:  2021-11-30       Impact factor: 4.599

4.  RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma.

Authors:  JinFeng Liu; Zhi Li; Iokfai Cheang; Jinghang Li; Chunlei Zhou
Journal:  Front Genet       Date:  2022-01-27       Impact factor: 4.599

5.  Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer.

Authors:  Lan He; Yanqi Huang; Xin Chen; Xiaomei Huang; Huihui Wang; Yuan Zhang; Changhong Liang; Zhenhui Li; Lixu Yan; Zaiyi Liu
Journal:  Front Immunol       Date:  2022-03-23       Impact factor: 7.561

6.  Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes.

Authors:  Kai Mi; Fuhui Chen; Zhipeng Qian; Jing Chen; Dongxu Lv; Chunlong Zhang; Yanjun Xu; Hongguang Wang; Yuepeng Zhang; Yanan Jiang; Desi Shang
Journal:  J Cell Mol Med       Date:  2020-11-12       Impact factor: 5.295

7.  Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer.

Authors:  Yuepeng Zhang; Kai Mi; Zhiheng Li; Lixia Qiang; Meiyu Lv; Yushan Wu; Ligong Yuan; Shoude Jin
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.